The shares of Hanesbrands Inc. (NYSE:HBI) has been pegged with a rating of Hold by Deutsche Bank in its latest research note that was published on January 11th, 2019. The research company has also assigned a $16 price target. Deutsche Bank wasn’t the only research firm that published a report of Hanesbrands Inc., with other equities research analysts also giving their opinion on the stock. Standpoint Research advised investors in its research note published on October 23rd, 2018, to Buy the HBI stock. The stock had earned Buy rating from Stifel when it published its report on April 23rd, 2018. That day the Stifel set price target on the stock to $23. The stock was given Neutral rating by BofA/Merrill in its report released on April 6th, 2018, the day when the price target on the stock was placed at $21. Macquarie was of a view that HBI is Neutral in its latest report on April 2nd, 2018 while giving it a price target of $19. Credit Suisse thinks that HBI is worth Neutral rating. This was contained in the firm’s report on March 13th, 2018 in which the stock’s price target was also moved to $21.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 8 believe it has the potential for further growth, thus rating it as Hold while 3 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $17.86. The price of the stock the last time has raised by 34.57% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 63.32.
The shares of the company dipped by -0.19% during the trading session on Wednesday, reaching a low of $15.33 while ending the day at $15.57. During the trading session, a total of 6.78 million shares were traded which represents a -9.68% decline from the average session volume which is 6.18M shares. HBI had ended its last session trading at 15.60. Hanesbrands Inc. currently has a market cap of $5.66B, while its P/E ratio stands at 12.30, while its P/E earnings growth sits at 0.85, with a beta of 0.81. Hanesbrands Inc. debt-to-equity ratio currently stands at 5.04, while its quick ratio hovers at 0.80. HBI 52-week low price stands at $11.57 while its 52-week high price is $22.65.
The company in its last quarterly report recorded $0.55 earnings per share which is below the $0.55 predicted by most analysts. The Hanesbrands Inc. generated $1,848.71 million in revenue during the last quarter, which is slightly lower than the $1,870.47 million predicted by analysts. In the second quarter last year, the firm recorded $0.45 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 18.18%. Hanesbrands Inc. has the potential to record 1.27 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Barclays published a research note on January 31st, 2019 where it informed investors and clients that Invesco Ltd. (NYSE:IVZ) is now rated as Equal Weight. Their price target on the stock stands at $19. Standpoint Research also rated IVZ as Initiated on October 23rd, 2018, with its price target of $46 suggesting that IVZ could surge by 4.52% from its current share price. Even though the stock has been trading at $18.72/share, analysts expect it to surge higher by -0.75% to reach $19.46/share. It started the day trading at $18.885 and traded between $18.54 and $18.58 throughout the trading session.
A look at its technical shows that IVZ’s 50-day SMA is 18.11 while its 200-day SMA stands at 23.32. The stock has a high of $35.03 for the year while the low is $15.38. The company’s P/E ratio currently sits at 7.33, while the P/B ratio is 0.86. The company’s average trading volume currently stands at 5.63M shares, which means that the short-interest ratio is just 2.32 days. Over the past seven days, the company moved, with its shift of -0.05%. Looking further, the stock has dropped -14.06% over the past 90 days while it lost -26.59% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc bought more IVZ shares, increasing its portfolio by +1.24% during the last quarter. This move now sees The Vanguard Group Inc purchasing 525,906 shares in the last quarter, thus it now holds 42,973,147 shares of IVZ, with a total valuation of $719,370,481. BlackRock Fund Advisors meanwhile bought more IVZ shares in the recently filed quarter, changing its stake to $415,466,896 worth of shares. American Century Investment Manag followed the path by increasing its IVZ portfolio by +19.77% in the quarter. This means that American Century Investment Manag bought 3,250,743 shares in the last quarter and now controls 19,693,259 shares of the IVZ stock, with the valuation hitting $329,665,156.
Similarly, JPMorgan Investment Management I increased its Invesco Ltd. shares by +12.59% during the recently filed quarter. After buying 1,135,767 shares in the last quarter, the firm now controls 10,158,358 shares of Invesco Ltd. which are valued at $170,050,913. In the same vein, UBS Financial Services Inc decreased its Invesco Ltd. shares by during the most recent reported quarter. The firm sold -1,475,468 shares during the quarter which decreased its stakes to 10,021,906 shares and is now valued at $167,766,706. Following these latest developments, around 0.50% of Invesco Ltd. stocks are owned by institutional investors and hedge funds.